Antimicrobial Resistance (AMR)
Bruker’s innovative FluoroType® PCR molecular diagnostic tests provide rapid, easy-to-use solutions, which help in early detection of AMR, allowing for timely interventions and optimized treatment plans.
Antimicrobial resistance (AMR) is highlighted by WHO as one of the top 10 global public health threats facing humanity. It is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths. AMR poses a significant threat to patients by diminishing the effectiveness of commonly used antimicrobial agents, leading to prolonged illnesses, increased healthcare costs, and higher mortality rates. Rapid and accurate diagnostics are crucial for monitoring resistant pathogenic strains, guiding healthcare providers in prescribing appropriate patient-specific antibiotics, and preventing treatment failures.
